There are 3164 resources available
1690O - NKT2152, a novel oral HIF-2α inhibitor, in participants (pts) with previously treated advanced clear cell renal carcinoma (accRCC): Preliminary results of a phase I/II study
Presenter: Eric Jonasch
Session: Proffered paper session 1: GU tumours, non-prostate
Resources:
Abstract
Slides
Webcast
444O - The prognostic impact of CDKN2A/B heterozygous deletions in IDH-mutant glioma
Presenter: Franziska Ippen
Session: Proffered paper session: CNS tumours
Resources:
Abstract
Slides
Webcast
804MO - Gut microbiota composition is predictive of CAR-T cells response and its modulation enhances CAR-T cells activity
Presenter: Laura MARCOS-KOVANDZIC
Session: Mini oral session 1: Haematological malignancies
Resources:
Abstract
Slides
Webcast
Conclusions and perspectives
Presenter: Christian Blank
Session: Why neoadjuvant immunotherapy is the future for melanoma
Resources:
Slides
Webcast
Conclusions and perspectives
Presenter: Yardena Samuels
Session: Beyond coding neoantigens: What else is there for T cells to see?
Resources:
Webcast
Conclusions and perspectives
Presenter: Neeltje Steeghs
Session: New endpoints in early clinical trials
Resources:
Slides
Webcast
Q&A
Session: Proffered Paper session: Non-metastatic NSCLC
Resources:
Webcast
LBA83 - PECATI: A phase II trial to evaluate the efficacy and safety of lenvatinib in combination with pembrolizumab in pretreated advanced B3-thymoma and thymic carcinoma
Presenter: Jordi Remon Masip
Session: Proffered Paper session: Non-metastatic NSCLC
Resources:
Abstract
Slides
Webcast
Invited Discussant 802MO, 803MO and 804MO
Presenter: Ya Hwee Tan
Session: Mini oral session 1: Haematological malignancies
Resources:
Slides
Webcast
Invited Discussant 1959O and 1690O
Presenter: Jonathan Rosenberg
Session: Proffered paper session 1: GU tumours, non-prostate
Resources:
Slides
Webcast